抗体药物偶联物治疗晚期实体瘤的不良反应和处理措施

Adverse reactions and treatment measures of advanced solid tumors treated with antibody-drug conjugates

新型抗体药物偶联物(ADC)是目前晚期实体瘤新药研发的热点,ADC药物在晚期乳腺癌、尿路上皮癌、胃癌等多种实体瘤治疗中具有显著疗效,但其眼毒性、肺毒性、血液学毒性、肝脏毒性等不良反应不可忽视,有效处理ADC药物的不良反应至关重要。

Novel antibody-drug conjugates(ADCs)are a hot spot in the research and development of new drugs for advanced solid tumors.ADCs have achieved significant efficacy in the treatment of advanced breast cancer,urothelial carcinoma,gastric cancer and other solid tumors,but their adverse reactions such as ocular toxicity,pulmonary toxicity,hematological toxicity,and liver toxicity cannot be ignored,and it is crucial to effectively deal with the adverse reactions of ADCs.